top of page

About
- Our Company
- Our Leadership Team
Science
Products
Pipeline
Newsroom
Contact
Investors
More

Use tab to navigate through the menu items.

Newsroom

All Posts
Publication
News

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

3 days ago

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

5 days ago

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

Dec 17, 2025

2 3 4 5

DNA Methylation

Investor Relations

Laboratory Developed Tests Services

Exosome Based Therapies

Clinical Trial Drug Distribution

Health Supplements

Privacy Statement

Data Rights Form

21720 23rd Dr. SE, Suite 275,

Bothell, WA 98021, USA

Email: info@ydesgroup.com

Tel: +1 (206) 888-0858

bottom of page